Evaluation of taurine as in osmotic agent for peritoneal dialysis solution

Peritoneal Dialysis International

Volumn 29, Issue 2, 2009, Pages 204-216

  Nishimura, Hideki ^a,b   Ikehara, Osamu ^a   Naito, Takashi ^a   Higuchu, Chieko ^a   Sanaka, Tsutomu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Biocompatibility; GDP; Osmolite; Peritoneal dialysis fluid; Taurine

Indexed keywords

GLUCOSE; OSMOLITE; PERITONEAL DIALYSIS FLUID; TAURINE; XYLITOL; DIALYSIS FLUID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; MALE; MESOTHELIUM CELL; MONOLAYER CULTURE; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; ULTRAFILTRATION; ANIMAL; ANIMAL MODEL; METABOLISM; OSMOLARITY; PERMEABILITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; MALE; MODELS, ANIMAL; OSMOLAR CONCENTRATION; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; TAURINE;

EID: 67149126577     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900216     Document Type: Article

References (41)

1. Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220:143-51.
2. Kumano K, Schiller B, Hjelle JT, Moran J. Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Blood Purif 1996; 14:165-9.
3. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999; 19:221-30.
4. Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial 2005; 9:173-81.
5. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004; 65:1170-9.
6. Ikehara O, Nishimura H, Naito T, Higuchi C, Sanaka T. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats. Nephron Exp Nephrol 2005; 100:e30-9.
7. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
8. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997; 17:52-8.
9. Mahiout A, Ehlerding G, Brunkhorst R. Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrol Dial Transplant 1996; 11(Suppl 5):2-6.
10. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid dialysis solution: a long-term, cross-over study. Kidney Int 1989; 35:1189-94.
11. Young GA, Dibble JB, Taylor AE, Kendall S, Brownjohn AM. A longitudinal study of the effects of amino acid-based CAPD fluid on amino acid retention and protein losses. Nephrol Dial Transplant 1989; 4:900-5.
12. Huxtable RJ. Physiological actions of taurine. Physiol Rev 1992; 72:101-63.
13. Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids 2002; 23:381-93.
14. Horiuchii T, Inoue T, Nagasawa K. Prolonged preservation of rat peritoneal mesothelial cells (RPMC) and rat peritoneal fibroblasts (RPFB) with neutral pH peritoneal dialysis solution depleted of glucose degradation products (GDPs). Clin Exp Nephrol 2001; 5:257-64.
15. Flessner MF, Schwab A. Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol 1996; 270: F377-F390.
16. Pannekeet MM, Imholz AL, Struijk DG, Koomen GC, Langedijk MJ, Schouten N, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
17. Suzuki K, Karino T, Namoto S, Wada M, Wakamiya Y, Yamamoto T. Tranexamic acid: a "diuretic" for the peritoneal membrane? Adv Perit Dial 2000; 16:42-5.
18. Krediet RT, Struijk DG, Koomen GC, Arisz L. Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991; 37:662-7.
19. Krediet RT. Fluid absorption in the peritoneum - it is less simple than you thought. Nephrol Dial Transplant 1994; 9:341-3.
20. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 1968; 13:222-57.
21. Bazzato G, Coli U, Landini S, Fracasso A, Morachiello P, Righetto F, et al. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients? Trans Am Soc Artif Intern Organs 1982; 28:280-6.
22. Holley JL, Moss AH. A prospective evaluation of blood culture versus standard plate techniques for diagnosing peritonitis in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1989; 13:184-8.
23. Gotloib L, Waisbrut V, Shostak A, Kushnier R. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 1995; 70:466-77.
24. Jonasson P, Braide M. A commercially available PD fluid with high pH and low GDP induces different morphological changes of rat peritoneum in intermittent PD. Adv Perit Dial 1998; 14:48-53.
25. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
26. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
27. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
28. Twardowski ZJ, Khanna R, Nolph KD. Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986; 42: 93-101.
29. Simchon S, Carlin RD, Jan KM, Chien S. A double isotope technique to determine regional albumin permeability: effects of anesthesia. Proc Soc Exp Biol Med 1990; 195: 114-18.
30. Zakaria ER, Rippe B. Intraperitoneal fluid volume changes during peritoneal dialysis in the rat: indicator dilution vs. volumetric measurements. Blood Purif 1995; 13:255-70.
31. Lallemand F, De Witte P. Taurine concentration in the brain and in the plasma following intraperitoneal injections. Amino Acids 2004; 26:111-16.
32. Dawson R Jr, Biasetti M, Messina S, Dominy J. The cytoprotective role of taurine in exercise-induced muscle injury. Amino Acids 2002; 22:309-24.
33. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
34. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/ lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
35. Fujihira E, Takahashi H, Nakazawa M. Effect of long-term feeding of taurine in hereditary hyperglycemic obese mice. Chem Pharm Bull (Tokyo) 1970; 18:1636-42.
36. Lindholm B, Alvestrand A, Furst P, Bergstrom J. Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis. Kidney Int 1989; 35:1219-26.
37. Suliman ME, Barany P, Filho JC, Lindholm B, Bergstrom J. Accumulation of taurine in patients with renal failure. Nephrol Dial Transplant 2002; 17:528-9.
38. Yamamoto S. Oral taurine therapy for painful muscle cramp in liver cirrhosis. Am J Gastroenterol 1994; 89: 457-8.
39. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44:230-4.
40. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7:198-207.
41. Mozaffari MS, Schaffer SW. Chronic taurine treatment ameliorates reduction in saline-induced diuresis and natriuresis. Kidney Int 2002; 61:1750-9.